Funded to deliver the first FDA-approved drug for Ménière's disease.

Spiral closed an oversubscribed Series B in 2026, led by Gund Investment, with participation from Ferring Ventures, Uni-Bio Science Group, and Advanced Bionics. The round funds SPT-2101 through IND filing and pivotal trial initiation, and advances the rest of the pipeline.

Gund Investment

Ferring Ventures